M&R Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

M&R Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-903	Closed	-$32K	–	584
2016 Q4	$32K	Buy	903 +500	+124%	+$20K	0.01%	325
2016 Q3	$18K	Buy	403 +3	+0.8%	+$157	0.01%	375
2016 Q2	$20K	Buy	+400	New	+$21.3K	0.01%	366
2014 Q1	–	Sell	-9,493	Closed	-$380	–	208
2013 Q4	$380	Sell	9,493 -5,800	-38%	-$228K	0.1%	133
2013 Q3	$578K	Sell	15,293 -1,900	-11%	-$74.1K	0.16%	99
2013 Q2	$674K	Buy	+17,193	New	+$670K	0.19%	86

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

M&R Capital Management's TEVA Position: Q1 2017 in Review

M&R Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 903 shares — an estimated $32K sold.

M&R Capital Management first reported a position in TEVA in Q2 2013 and held it in 6 quarters. The position peaked at $674K in Q2 2013. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

M&R Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
M&R Capital Management sold 903 Teva Pharmaceuticals shares in Q1 2017, an estimated $32K.
M&R Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 6 quarters.
M&R Capital Management's Teva Pharmaceuticals position peaked at $674K in Q2 2013.
686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on M&R Capital Management's 13F filing for Q1 2017, filed 15 May 2017.